Literature DB >> 23748345

Pim kinases phosphorylate Chk1 and regulate its functions in acute myeloid leukemia.

L L Yuan1, A S Green2, S Bertoli3, F Grimal1, V Mansat-De Mas4, C Dozier1, J Tamburini2, C Récher3, C Didier1, S Manenti1.   

Abstract

Phosphorylation by Akt on Ser 280 was reported to induce cytoplasmic retention and inactivation of CHK1 with consequent genetic instability in PTEN-/- cells. In acute myeloid leukemia cells carrying the FLT3-internal tandem duplication (ITD) mutation, we observed high rates of FLT3-ITD-dependent CHK1 Ser 280 phosphorylation. Pharmacological inhibition and RNA interference identified Pim1/2, not Akt, as effectors of this phosphorylation. Pim1 catalyzed Ser 280 phosphorylation in vitro and ectopic expression of Pim1/2-induced CHK1 phosphorylation. Ser 280 phosphorylation did not modify CHK1 localization, but facilitated its cell cycle and resistance functions in leukemic cells. FLT3, PIM or CHK1 inhibitors synergized with DNA-damaging agents to induce apoptosis, allowing cells to bypass the etoposide-induced G2/M arrest. Consistently, etoposide-induced CHK1-dependent phosphorylations of CDC25C on Ser 216 and histone H3 on Thr11 were decreased upon FLT3 inhibition. Accordingly, ectopic expression of CHK1 improved the resistance of FLT3-ITD cells and maintained histone H3 phosphorylation in response to DNA damage, whereas expression of unphosphorylated Ser 280Ala mutant did not. Finally, FLT3- and Pim-dependent phosphorylation of CHK1 on Ser 280 was confirmed in primary blasts from patients. These results identify a new pathway involved in the resistance of FLT3-ITD leukemic cells to genotoxic agents, and they constitute the first report of CHK1 Ser 280 regulation in myeloid malignancies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23748345     DOI: 10.1038/leu.2013.168

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  34 in total

1.  Centrosome-associated Chk1 prevents premature activation of cyclin-B-Cdk1 kinase.

Authors:  Alwin Krämer; Niels Mailand; Claudia Lukas; Randi G Syljuåsen; Christopher J Wilkinson; Erich A Nigg; Jiri Bartek; Jiri Lukas
Journal:  Nat Cell Biol       Date:  2004-08-15       Impact factor: 28.824

2.  Chk1 promotes replication fork progression by controlling replication initiation.

Authors:  Eva Petermann; Mick Woodcock; Thomas Helleday
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-30       Impact factor: 11.205

3.  Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial.

Authors:  Deepa Sampath; Jorge Cortes; Zeev Estrov; Min Du; Zheng Shi; Michael Andreeff; Varsha Gandhi; William Plunkett
Journal:  Blood       Date:  2005-11-17       Impact factor: 22.113

Review 4.  PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers.

Authors:  Laurent Brault; Christelle Gasser; Franz Bracher; Kilian Huber; Stefan Knapp; Jürg Schwaller
Journal:  Haematologica       Date:  2010-02-09       Impact factor: 9.941

5.  Aromatic interactions with phenylalanine 691 and cysteine 828: a concept for FMS-like tyrosine kinase-3 inhibition. Application to the discovery of a new class of potential antileukemia agents.

Authors:  Pascal Furet; Guido Bold; Thomas Meyer; Johannes Roesel; Vito Guagnano
Journal:  J Med Chem       Date:  2006-07-27       Impact factor: 7.446

6.  Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3.

Authors:  Donatella Amico; Anna Maria Barbui; Eugenio Erba; Alessandro Rambaldi; Martino Introna; Josee Golay
Journal:  Blood       Date:  2003-02-06       Impact factor: 22.113

7.  Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia.

Authors:  Jerome Tamburini; Alexa S Green; Valerie Bardet; Nicolas Chapuis; Sophie Park; Lise Willems; Madalina Uzunov; Norbert Ifrah; François Dreyfus; Catherine Lacombe; Patrick Mayeux; Didier Bouscary
Journal:  Blood       Date:  2009-05-20       Impact factor: 22.113

8.  G2/M checkpoint stringency is a key parameter in the sensitivity of AML cells to genotoxic stress.

Authors:  C Didier; C Cavelier; M Quaranta; M-O Galcera; C Demur; G Laurent; S Manenti; B Ducommun
Journal:  Oncogene       Date:  2008-01-21       Impact factor: 9.867

Review 9.  New insights into checkpoint kinase 1 in the DNA damage response signaling network.

Authors:  Yun Dai; Steven Grant
Journal:  Clin Cancer Res       Date:  2010-01-12       Impact factor: 12.531

10.  Akt activation emulates Chk1 inhibition and Bcl2 overexpression and abrogates G2 cell cycle checkpoint by inhibiting BRCA1 foci.

Authors:  Ivana Tonic; Wan-Ni Yu; Youngku Park; Chia-Chen Chen; Nissim Hay
Journal:  J Biol Chem       Date:  2010-05-21       Impact factor: 5.157

View more
  16 in total

1.  Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia.

Authors:  Lisa S Chen; Ji-Yeon Yang; Han Liang; Jorge E Cortes; Varsha Gandhi
Journal:  Leuk Lymphoma       Date:  2016-04-07

Review 2.  The role of Pim kinase in immunomodulation.

Authors:  Zhaoyun Liu; Mei Han; Kai Ding; Rong Fu
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

Review 3.  DNA damage accumulation and repair defects in acute myeloid leukemia: implications for pathogenesis, disease progression, and chemotherapy resistance.

Authors:  Maria Teresa Esposito; Chi Wai Eric So
Journal:  Chromosoma       Date:  2014-08-12       Impact factor: 4.316

4.  Cytoplasmic Irradiation Induces Metabolic Shift in Human Small Airway Epithelial Cells via Activation of Pim-1 Kinase.

Authors:  Jinhua Wu; Qin Zhang; Yen-Ruh Wuu; Sirui Zou; Tom K Hei
Journal:  Radiat Res       Date:  2017-02-07       Impact factor: 2.841

5.  PIM1 regulates glycolysis and promotes tumor progression in hepatocellular carcinoma.

Authors:  Carmen Oi-ning Leung; Carmen Chak-lui Wong; Dorothy Ngo-yin Fan; Alan Ka-lun Kai; Edmund Kwok-kwan Tung; Iris Ming-jing Xu; Irene Oi-lin Ng; Regina Cheuk-lam Lo
Journal:  Oncotarget       Date:  2015-05-10

Review 6.  Targeting the Pim kinases in multiple myeloma.

Authors:  N A Keane; M Reidy; A Natoni; M S Raab; M O'Dwyer
Journal:  Blood Cancer J       Date:  2015-07-17       Impact factor: 11.037

7.  A regulatory feedback loop between HIF-1α and PIM2 in HepG2 cells.

Authors:  Zhenhai Yu; Xiaoping Zhao; Yingying Ge; Teng Zhang; Liangqian Huang; Xiang Zhou; Lei Xie; Jianjun Liu; Gang Huang
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

8.  CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.

Authors:  Sarah Bertoli; Helena Boutzen; Laure David; Clément Larrue; François Vergez; Anne Fernandez-Vidal; Lingli Yuan; Marie-Anne Hospital; Jérôme Tamburini; Cécile Demur; Eric Delabesse; Estelle Saland; Jean-Emmanuel Sarry; Marie-Odile Galcera; Véronique Mansat-De Mas; Christine Didier; Christine Dozier; Christian Récher; Stéphane Manenti
Journal:  Oncotarget       Date:  2015-11-10

9.  Fms-like tyrosine kinase 3-internal tandem duplications epigenetically activates checkpoint kinase 1 in acute myeloid leukemia cells.

Authors:  Yudong Zhang; Lingli Yuan
Journal:  Sci Rep       Date:  2021-06-24       Impact factor: 4.379

10.  Control of Pim2 kinase stability and expression in transformed human haematopoietic cells.

Authors:  Kévin Adam; Mireille Lambert; Elsa Lestang; Gabriel Champenois; Isabelle Dusanter-Fourt; Jérôme Tamburini; Didier Bouscary; Catherine Lacombe; Yael Zermati; Patrick Mayeux
Journal:  Biosci Rep       Date:  2015-10-23       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.